Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Trial Parameters
Brief Summary
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years and ≤ 65 years * Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL) * Any stage of disease (nodal or extra-nodal), with or without B symptoms * Scheduled to receive standard systemic treatment (R-CHOP) * ECOG performance status 0-2 * Baseline normal: * Complete blood count (CBC) * Hepatitis viral markers * Liver and renal function tests * Urine analysis * Echocardiogram * Additional investigations to exclude current infection if clinically indicated Exclusion Criteria: * History of other concurrent or previous malignancies * Relapsed or refractory DLBCL * Uncontrolled comorbid conditions that may interfere with study participation, including: * Diabetes mellitus * Autoimmune diseases * Active infections * Chronic inflammatory diseases * Cardiac dysfunction * Liver cell failure * Pregnant females